<DOC>
	<DOCNO>NCT00048620</DOCNO>
	<brief_summary>The purpose study evaluate safety , efficacy pharmacokinetics two dose level weekly intravenous infusion recombinant human N-acetylgalactosamine 4-sulfatase ( rhASB ) minimum 24 week patient diagnose MPS VI .</brief_summary>
	<brief_title>Study Recombinant Human N-Acetylgalactosamine 4-Sulfatase Patients With MPS VI</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis VI</mesh_term>
	<criteria>Patient consent Patient must five year age old Patient must document diagnosis MPS VI , confirm screen measurable clinical sign symptom MPS VI Leukocyte ASB enzyme activity level le 20 % normal range Clinical evidence significant MPS VI disease provide adequate opportunity achieve quantitative , shortterm therapeutic benefit three follow parameter : endurance ( measure sixminute walk test ) , force vital capacity ( measured spirometry ) , joint range motion , urinary glycosaminoglycans , hepatomegaly . Ability perform protocol test Ability stand independently six minute Sexually active subject must agree use adequate form contraception History bone marrow transplantation Pregnant lactating patient Use investigational drug device within 30 day prior study participation . A medical condition , serious intercurrent illness , extenuate circumstance may significantly decrease study compliance include prescribed followup Known hypersensitivity rhASB component study drug History cancer ( except low grade fully resolve skin malignancy )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
</DOC>